First patients sought for groundbreaking trial targeting rare, aggressive cancers
NCT ID NCT06041516
Summary
This is the first-ever study in people for a new drug called ADCT-701, designed for adults with rare and hard-to-treat cancers like neuroendocrine tumors and malignant peripheral nerve sheath tumors. The main goal is to find the safest and most effective dose by giving the drug through an IV every three weeks. Researchers will enroll about 70 participants to carefully monitor how their bodies handle the treatment and to see if it shows any early signs of helping control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, ADRENOCORTICAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.